1-5 of 5
Keywords: therapeutics
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Biochem J (2022) 479 (6): 731–750.
Published: 28 March 2022
... of identifying new therapeutics to block immunothrombotic triggering of TF, which can involve inhibition of pyroptosis to limit TF release, or the direct targeting of TF decryption using cysteine-modifying therapeutics. Correspondence: Tristram A. J. Ryan ( ryant9@tcd.ie ) 14 12 2021 9 3 2022...
Biochem J (2022) 479 (5): 609–628.
Published: 04 March 2022
... and their pathways and molecular components therefore present promising targets for host-directed therapeutics. In our review, we summarize the current knowledge on the role and impact of diverse programmed cell death (PCD) pathways on COVID-19 disease. We dissect the complex connection of cell death...
Biochem J (2020) 477 (15): 2893–2919.
Published: 14 August 2020
... 2020 22 7 2020 © 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2020 cancer phospholipids plasma membrane RAS small molecule inhibitors therapeutics RAS proteins are part of a superfamily of more than 150 low molecular mass GTP...
Biochem J (2020) 477 (8): 1363–1366.
Published: 23 April 2020
...Giovanna Maria Pierantoni; Simona Paladino Cell-penetrating peptides (CPPs) are short peptides able to cross the cellular membranes without any interaction with specific receptors. Thanks to their ability to transport various cargo inside the cells are emerged as powerful therapeutic agents...
Biochem J (2014) 464 (3): 301–313.
Published: 05 December 2014
...), and that the α1 helix in the β subunit I domain is the key element affected by allosteric modulators. The data suggest an explanation for the limited clinical efficacy of RGD-based integrin antagonists, and we propose that allosteric antagonists could prove to be of greater therapeutic benefit. 1 To whom...
Includes: Supplementary data